Study design: Phase 3, randomised, placebo-controlled study of 847 adult and adolescent (≥12 years of age) patients with moderate to severe AD. Patients were randomised 1:1:1 to RINVOQ 15 mg (n=281) or 30 mg (n=285) QD monotherapy, or placebo (n=281). The co-primary endpoints (EASI 75 & vIGA-AD 0/1 at Week 16,
ITT [NRI-C]) were met with both doses (p<0.001 vs placebo, multiplicity-controlled analysis). Response rate was assessed among subjects with a baseline DLQI ≥4.6
AD, atopic dermatitis; DLQI, Dermatology Life Quality Index; EASI, Eczema Area and Severity Index; EASI 75, ≥75% reduction in EASI; MCID, minimal clinically important difference; NRI-C, nonresponder imputation incorporating Multiple Imputation to handle missing data due to COVID-19; OD, once daily; TCS, topical corticosteroids; vIGA-AD, Validated Inspector's Global Assessment for atopic dermatitis.